Skip to main content
. 2020 Dec 18;16(5):1341–1356. doi: 10.1007/s11739-020-02589-5

Fig. 2.

Fig. 2

a Forest plot evaluating the effect of muscle mass on DLT due to TKI treatment (sorafenib, sunitinib). b Subgroup analysis by TKI type. CI confidence interval; DLT dose-limiting toxicity; IV inverse variance